Roche RHHBY announced that the FDA has accepted its new drug application (NDA) for its investigational candidate, ...

To Roche, a phase 3 flop in first-line breast cancer does not erase the megablockbuster potential of its oral SERD drug ...

Investors might want to bet on Roche Holding AG (RHHBY), as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one ...

Roche (RHHBF) stock is in focus as the FDA grants priority review for breast cancer therapy giredestrant with a target action ...

PathAI’s best-in-class Image Management System (IMS) with advanced AI analysis and workflow capabilities will complement Roche's digital pathology portfolio to drive laboratory efficiencyCombining ...

(Reuters) -Roche shares gained as much as 4.7% on Thursday after an early-stage trial showed that a newly-acquired obesity drug candidate led to significant weight loss, a key step in Swiss ...

This year's American Society of Clinical Oncology (ASCO) conference has been a subdued affair for European pharmaceutical ...

New giredestrant data from the lidERA study on its potential as a new standard of care for adjuvant ER-positive breast cancer ...

ZURICH, May 7 (Reuters) - Swiss pharmaceutical giant Roche said on Thursday it had agreed to acquire U.S.-based digital pathology and AI-powered technology firm PathAI in a deal worth $750 million ...

Jonathan Wosen is STAT’s West Coast biotech & life sciences reporter. You can reach Jonathan on Signal at jwosen.27. Swiss pharma giant Roche won approval from the ...

The agreement could generate an additional $300 million for PathAI if the it leads to the achievement of certain milestones.